Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8042-8047

  Hayashida, Yasuharu ^a,b   Honda, Kazufumi ^a   Osaka, Yoshiaki ^b   Hara, Tomohiko ^a   Umaki, Tomoko ^a   Tsuchida, Akihiko ^b   Aoki, Tatsuya ^b   Hirohashi, Setsuo ^a   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PLASMA PROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD SAMPLING; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CANCER; FEMALE; HUMAN; JAPAN; MALE; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEOMICS; RADIOSENSITIVITY; RELIABILITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

AGED; BLOOD PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 28144441052     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0656     Document Type: Article

References (27)

1. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-10.
2. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
3. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30.
4. Osaka Y, Takagi Y, Tsuchida A, et al. Concurrent preoperative chemoradiotherapy for stage III or IV esophageal squamous carcinoma. Oncol Rep 2004; 12:1121-6.
5. Osaka Y, Takagi T, Hoshino S, et al. Effective of preoperative chemoradiotherapy for advanced esophageal carcinoma. Nihon Gekakei Rengogakkai Zasshi 2004; 29:6-12.
6. Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221:685-95.
7. Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and post-operative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-76.
8. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-74.
9. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-92.
10. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumor subsets in on-small-cell lung cancer. Lancet 2003;362:433-9.
11. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7
12. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62: 3609-14.
13. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003;100: 12343-8.
14. Zhang Z, Bast RC, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
15. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
16. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
17. The Japanese Society for Esophageal Disease. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. In: Isono K, editor. 9th ed. Tokyo: Kanehara Shuppan; 2001.
18. Gras R, Muller M, Gasteiger E, et al. Improving protein identification from peptide mass fingerprinting through a parameterized multi-level scoring algorithm and an optimized peak detection. Electrophoresis 1999;20:3535-50.
19. Byvatov E, Schneider G. Support vector machine applications in bioinformatics. Appl Bioinformatics 2003;2:67-77.
20. Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Machine Learning 2002;46: 389-422.
21. Honda K, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res, in press.
22. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
23. Boguski MS, McIntosh MW. Biomedical informatics for proteomics. Nature 2003;422:233-7.
24. Gershon D. Proteomics technologies: probing the proteome. Nature 2003;424:581-7.
25. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905.
26. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid α in renal cancer patients. Lab Invest 2004;84:845-56.
27. Shimada H, Hoshino T, Okazumi S, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of esophageal squamous cell carcinoma. Br J Cancer 2002;86:552-7.